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Improved survival prognostication 
of node-positive malignant 
melanoma patients utilizing 
shotgun proteomics guided by 
histopathological characterization 
and genomic data
Lazaro Hiram Betancourt1, Krzysztof Pawłowski  1,2, Jonatan eriksson1, A. Marcell szasz1,4,5, 
shamik Mitra1, Indira pla  1, Charlotte Welinder1, Henrik ekedahl1, per Broberg1, 
Roger Appelqvist1, Maria Yakovleva1, Yutaka sugihara1, Kenichi Miharada  1, 
Christian Ingvar1, Lotta Lundgren1, Bo Baldetorp1, Håkan olsson1, Melinda Rezeli1, 
elisabet Wieslander1, peter Horvatovich  1,3, Johan Malm1, Göran Jönsson1 &  
György Marko-Varga1,6
Metastatic melanoma is one of the most common deadly cancers, and robust biomarkers are still 
needed, e.g. to predict survival and treatment efficiency. Here, protein expression analysis of one 
hundred eleven melanoma lymph node metastases using high resolution mass spectrometry is coupled 
with in-depth histopathology analysis, clinical data and genomics profiles. This broad view of protein 
expression allowed to identify novel candidate protein markers that improved prediction of survival 
in melanoma patients. Some of the prognostic proteins have not been reported in the context of 
melanoma before, and few of them exhibit unexpected relationship to survival, which likely reflects the 
limitations of current knowledge on melanoma and shows the potential of proteomics in clinical cancer 
research.
The incidence of malignant melanoma is increasing worldwide, particularly in Western countries, and survival 
does not seem to improve substantially1. Primary surgery is curative in most patients but around 10–15% of 
tumors are showing progression. Thus, it is important to early identify those patients who carry a skin tumor with 
progressive pathobiology. Currently, Breslow thickness is the most accurate tool for predicting the disease out-
come of primary melanoma2. To improve the prediction of disease outcome, more fine-tuned molecular profiling 
and data integration tools and efforts are needed to search for alternative biomarkers3.
Metastatic melanoma (MM) still remains a tumor with poor outcome4,5 despite interventions with targeted 
therapy and antibody-driven modulation of the immune response6–11.
Recent technological developments utilizing both genomic and proteomic analysis provide the opportunity 
to identify better predictive markers of melanomas12–16. It is possible to monitor the expression of certain genes 
and also gain understanding how these genes are expressed and regulated as functional proteins. Accordingly, 
detailed, personalized information on gene and protein expression and regulation, as well as data on specific 
mutations that may guide the treatment, can be monitored. Another cornerstone of prognostic predictions is 
1Lund University, Lund, Sweden. 2Warsaw University of Life Sciences SGGW, Warszawa, Poland. 3University 
of Groningen, Groningen, The Netherlands. 4National Koranyi Institute of Pulmonology, Budapest, Hungary. 
5Semmelweis University, Budapest, Hungary. 6Tokyo Medical University, Tokyo, Japan. Lazaro Hiram Betancourt, 
Krzysztof Pawłowski, Jonatan Eriksson and A. Marcell Szasz contributed equally. Correspondence and requests for 
materials should be addressed to K.P. (email: krzysztof_pawlowski@sggw.pl) or G.M.-V. (email: gyorgy.marko-
varga@bme.lth.se)
Received: 20 August 2018
Accepted: 13 March 2019
Published: xx xx xxxx
opeN
2Scientific RepoRts |          (2019) 9:5154  | https://doi.org/10.1038/s41598-019-41625-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
clinicopathological characterization based on high quality pathological and clinical information. Equally impor-
tant is to investigate the cellular composition of the tissue, to morphologically assess in detail the quality of tumor 
samples submitted for analysis and the identification of features important for disease progression.
In this study, we combine in depth histopathology analysis of melanoma lymph node metastases with 
deep-mining protein expression analysis using high-resolution mass spectrometry and a complex bioinformatics 
workflow to integrate clinical data with protein and genomics profile information. The protein data is matched to 
genomic analysis of the same tumor tissue. This information coupled with extensive clinical information on each 
subject provides an excellent opportunity to identify novel protein markers to predict progression and survival 
of melanoma.
Results and Discussion
Clinical data. A total of 111 patients diagnosed with melanoma metastasis between 1975 and 2011 were 
evaluated in the study (Table 1). There were 68 men and 43 women among the investigated cases. Average 
age ± standard deviation (range) at diagnosis of lymph node metastasis was 62.4 ± 13.7 (25–89) years. The time 
elapsed to progression from primary tumor to lymph node metastasis was 5.0 ± 5.6 (0–18.0) years and overall 
survival was 7.9 ± 6.8 (0.2–43.0) years. The dominant histotypes of primary tumors were Superficial Spreading 
Melanoma (SSN) and Nodular Melanoma (NM) (see Table 1). The cohort included 59% of patients with wild type 
BRAF status and 36% of patients with V600E mutation in the BRAF gene (4% had V600A or V600K mutation).
Histopathological data. Frozen specimens (snap frozen immediately after surgery) were subjected to this 
evaluation. In order to relate protein expression data to the tumor cellular composition, histological analyses 
were performed on the frozen tissue sections adjacent to sections used for mass spectrometry (see Methods). 
Parameters such as tumor content, surrounding lymph node area, necrosis and connective tissue percentages and 
lymphocytic infiltration were examined by a certified pathologist (Table 2).
The range of tumor content was 0 to 100%, and for most downstream analyses the inclusion criterion was to 
have at least 15% neoplasm of the tissue. The pieces for this analysis were removed from the surgically resected 
sample at macroscopic examination (grossing), thus, their content cannot represent the whole material excised 
from the patient. Nevertheless, assuming that histopathological properties in lymph node metastases display 











upper extremity 12 11























V600E mut 38 34
V600K mut 3 3
V600A mut 1 1
WT 64 58
Table 1. Clinicopathological information about the patients and patient samples. Histological types: ALM - 
acral lentiginous melanoma, SSM - superficial spreading melanoma, NM - nodular melanoma, LMM - lentigo 
maligna melanoma.
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were mostly composed of epithelioid shaped melanocytes infiltrating the lymph nodes, displaying necrosis to 
various extent, the background was lymphocytic sheets of otherwise normally appearing lymph nodes, in most 
cases with connective tissue present (Fig. 1A,B, Table 2).
proteomics data. Samples were analysed by high-resolution tandem mass spectrometry. Label-free LC-MS/
MS analysis allowed the quantitation of 4963 proteins, and more than one third of them was quantified in more 
than 50% of samples (see Suppl. Fig. S1). Most analyses of protein expression data, e.g. correlation with tumor 
content/percentage and patient overall survival, were restricted to 1306 proteins, i.e. those quantified in at least 
70% of the samples.
Relationship of protein expression to tumor content. In this relatively heterogeneous sample set, 
many proteins exhibited significant correlation to histopathological features. Two hundred and five proteins were 
significantly positively correlated to sample tumor cell content (using unadjusted p-value < 0.0001) and a smaller 
number, 29 proteins, were negatively correlated. As expected, the proteins correlated to tumor cell content usually 
showed inverse correlation to connective tissue content. In principle, correlation p-values should be adjusted 
for multiple testing using Benjamini-Hochberg (BH) approach. Approximately, the conservative raw p-value of 
0.0001 used here corresponds to the value of 0.006 after the BH correction (Suppl. Table ST7).
Positive and negative correlation of protein expression to tumor cell content was connected to particular 
molecular and biological functions. A Panther18 analysis of tumor cell-correlated proteins yielded molecular 
functions such as tRNA ligases and glycogen phosphorylases for the positively correlated set, while complement 
Samples’ properties: mean sd min max
tumor % 66 33 0 99
necrosis % 5 11 0 63
lymph node % 12 23 0 97
connective tissue % 17 26 0 100
Tumor properties n %
tumor cell size
<20 microns 98 88
20–25 microns 2 2
>25 microns 1 1
tumor cell shape
epithelioid 82 74


























Table 2. Tumor and tumor samples properties. Tumor cell pigmentation (0 = absent: no melanin pigment 
discernible even at high power magnification, 1 = slight: melanin pigmentation hardly visible at low power, at 
high power, melanocytes show a faint diffuse hue or a few scattered melanin pigment granules, 2 = moderate: 
pigmentation visible at low power, the cytoplasm is translucent and appears significantly lighter than the 
hematoxylin stained nuclei, 3 = high: pigmentation is easily visible at low power, the cytoplasmic pigmentation 
reaches an intensity approximating that of the nucleus). Lymphocyte distribution (0 = no lymphocytes within 
the tissue, 1 = lymphocytes present involving <25% of the tissue cross sectional area, 2 = lymphocytes present 
in 25 to 50% of the tissue, 3 = lymphocytes present in >50% of tissue). Lymphocyte density (0 = absent, 
1 = mild, 2 = moderate, 3 = severe).
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activation, structural constituent of cytoskeleton and actin-binding characterized the proteins negatively corre-
lated to tumor content. Similarly, an Ingenuity Pathway Analysis (IPA) performed for the tumor-correlated pro-
teins provided relationship networks enriched in proteins related to transcription, translation, glycolysis, tRNA 
charging, ubiquitination, tubulins, and splicing (See Suppl. Fig. S2 and Suppl. Table ST1). Similar functional 
themes were found to be associated with tumor cell content in a smaller subset of the current cohort analysed 
previously19, thus, confirming our earlier pilot findings. These functions are in line with well-known features of 
malignant tumors and connective tissues, and suggest that proteomics data could be used for tissue discrimina-
tion and quality assessment of the sample with respect to tumor content20.
Unsupervised view of the data - pCA. A non-supervised multivariate analysis of proteome profile allows 
to explore the main components of variability between the melanoma samples. Here, a principal component 
analysis (PCA) of protein expression data did not show obvious separation with respect to clinical or histopatho-
logical parameters (e.g. BRAF mutation status, survival, see Suppl. Fig. S7A,B). The only exception was tumor cell 
content, where a clear trend was visible (see Fig. 1C,D) indicating that sample heterogeneity in terms of tumor cell 
content was a major source of variability in the proteomics data.
Relating proteomics data to survival. In order to relate protein expression in lymph node metastatic 
melanomas to patient survival, we attempted an unsupervised classification based on consensus clustering21. 
This approach, applied to the whole sample set (111 patients) produced clusters that did not differ significantly 
in survival (Suppl Fig. S3A,B). Thus, for subsequent analyses only the 96 samples with tumor content of at least 
15% were considered (choosing higher thresholds did not improve survival prediction while obviously lowered 
the number of available samples). Here, we investigated the predictive power of the protein expression data from 
metastatic melanoma using two approaches. The unsupervised approach involved hierarchical consensus clus-
tering. The supervised approach consisted of Partial Least Square (PLS) regression in combination with Cox 
Proportional Hazards modeling (PLS-Cox). Both approaches were able to produce patient clusters with signif-
icant differences in survival. Applying unsupervised clustering to the proteomic data produced three patient 
clusters which show distinct differences in survival (log-rank test p-value = 0.0028, see Fig. 2A).
The PLS-Cox model reduces the expression of the whole feature-set (~1300 proteins) to a single latent (inferred) 
variable, which explains the main part of the variability with respect of patient survival and which is then used in 
a Cox Proportional Hazards model. A high score on this latent variable is linked to a low hazard score, i.e. better 
prognosis. Furthermore, we used rank products to extract the features (proteins) which contribute most to the 
latent variable22. After cross-validation and FDR testing, we obtained 27 proteins which were strong contributors 
Figure 1. Variability of the tumor samples. (A,B) Representative histopathology images of the tumor 
samples. (A) Low tumor content sample. Ly – lymphatic cells, M – tumor. (B) High tumor content sample. C – 
connective tissue. (C,D) Unsupervised multidimensional analysis of the proteomics data. Colouring by tumor 
content (dark: high content). Samples with <15% tumor shown as triangles, others – as circles. (C) Partial Least 
Squares (PLS) analysis. (D) Principal Component Analysis (PCA).
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to the latent variable (see Suppl. Table ST2). Of these, 9 were positively correlated (thus high expression is linked to 
long survival) and 18 negatively correlated (overexpression of these is linked to short survival).
When applied to only the 27 proteins obtained from the PLS-Cox model, the same hierarchical clustering 
algorithm gave us three patient clusters, even more distinct in terms of survival (log-rank test p-value = 0.000066, 
see Fig. 2B). One of the clusters corresponded to poor survival and was characterized by downregulation of the 
9 proteins positively correlated and by upregulation of the 18 proteins negatively correlated to survival. A second 
cluster had expression profiles opposite to those of the first one and corresponded to a more favourable survival. 
A third cluster corresponded to intermediate survival and an intermediate expression pattern (see Fig. 2C).
Analogous analyses were performed using peptide quantitation data. Here, unsupervised consensus and 
supervised PLS-Cox clustering also produced clusters significantly differing in survival, albeit with weaker effect.
In order to ascertain that the 15% tumor content cutoff was not too subjective, several other cutoffs were tested 
(0, 25, 50 and 75% tumor) and the PLS-Cox survival analysis was repeated for each. The 15, 25 and 50% cutoffs 
produced very similar results in terms of candidate survival biomarker sets (Suppl. Table ST6), albeit the 15% 
threshold provided the largest number of significant candidates (twenty seven). Also, the 15% cutoff provided 
the most significant statistical model while the 25% cutoff resulted in a model of similar significance (Suppl. 
Table ST9).
Further, the Cox survival analysis was performed using several histological features of the samples instead of 
protein expression data (see Suppl. Table ST8). While some such features (related to cytoplasm features) did show 
a weak relationship to survival (univariate Cox regression model p-values 0.003–0.03), protein expression clearly 
outperformed these features in terms of survival prediction. All univariate Cox models built for the 27 candidate 
proteins were significant and most had p-values below 0.003 (minimum 3*10−6, see Suppl. Table ST10). Of note, 
tumor content was not a significant survival predictor (see Suppl. Table ST8).
The PLS-Cox based supervised clustering built on protein expression was compared with two genomics-based 
sample classifications applied previously to the same tumor samples. The four-category classification of Jönsson 
et al. (high immune, normal, pigmentation and proliferative23) and TCGA classification (immune, keratin, 
MITF-low16) were not in perfect accordance with the three survival clusters elucidated herein (see Fig. 3 and 
Suppl. Fig. S4A,B). However, there were clear differences between the longer and shorter survival clusters in 
terms of composition of the genomics categories. Interestingly, the short survival cluster 2 had largest propor-
tion of proliferative-type tumors (Jönsson’s classification23) while the long survival cluster 3 had approx. 75% 
samples of the pigmentation type. In terms of TCGA classification16, short survival cluster 2 had largest pro-
portion of MITF-low tumors while the long and medium survival clusters 1 and 3 had largest proportion of 
immune-type tumors (Suppl. Fig. S4). The long survival clusters obtained by two approaches (unsupervised and 
supervised) using protein data agreed well - they were composed mostly of the same patient samples (90% agree-
ment, i.e.: 90% of the samples from the supervised good prognosis cluster belonged also to the unsupervised 
good prognosis cluster). The same applies to the short survival clusters (78% agreement, see Suppl. Fig. S4C). The 
chi-squared test comparing the unsupervised and supervised patient sample clustering supports their consistency 
(p-value < 10−5). Interestingly, the short survival cluster (supervised) had significantly higher necrosis content 
than other clusters (Kruskal-Wallis p-value < 10−6, see Suppl. Fig. S6).
Although for the survival prediction model there was no independent proteomics validation cohort available, 
we performed a tentative validation of the candidate proteomic survival biomarkers found in our study by using a 
large transcriptomic dataset of melanoma lymph node metastases (TCGA, N = 336, see Materials and Methods). 
Several of the 27 candidate biomarkers could be validated in this independent cohort, including those positively 
related to survival (high expression in long survival): PSME1, HNRNPA2B1 and SRSF3, and those negatively 
related to survival (high expression in short survival): APOB and ORM1 (see Suppl. Table ST5). This result is 
encouraging, bearing in mind the fact that on the average the corresponding signals for mRNA and protein 
expression correlate moderately.
Figure 2. Proteomics data is related to patient survival. (A,B) 2A. Kaplan Meier plots for patient clusters 
obtained by (A) consensus clustering using 1306 proteins quantified in at least 70% of the samples (shown in 
Suppl. Fig. S3C) (B) consensus clustering using only the 27 survival-related proteins, with significant Cox scores 
(shown in Suppl. Fig. S3D). (C) Two-way hierarchical clustering of the 27 survival-related proteins and the 
patient samples. Red: high expression. Blue: low expression. Patient clusters coloured as in (B).
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Functional analysis of the survival-related clusters. The three clusters obtained by supervised 
PLS-Cox analysis24 of proteomics data and significantly differing in survival were explored in order to under-
stand the molecular differences. To this end, the current proteomic data and mRNA expression data obtained 
previously for the same melanoma samples23, were subjected to SAM analysis (a technique conceptually similar 
to ANOVA25) to obtain genes and proteins differentially expressed between sample clusters. The analyses included 
more than 1300 proteins and more than 11000 genes. At significance level of FDR < 0.0005, 419 proteins and 177 
genes were found to be differentially expressed between the three clusters (1368 proteins and 777 genes at more 
relaxed significance level of FDR < 0.05). The heatmaps in Fig. 3A,B show the genes/proteins with cluster-specific 
expression patterns. Within the three clusters, cluster 3 (long survival) clearly had underrepresentation of mela-
nomas that were stage 4 while cluster 2 (poor survival) clearly had overrepresentation of stage 4 melanomas (see 
Fig. 3A,B).
The sets of proteins and genes significantly differing between the three survival-related patient clusters were 
rather different (for FDR < 0.0005, overlap between the 419 proteins and the 177 genes was only 8, while for 
FDR < 0.05, the gene/protein list overlap was 68, see Suppl. Table ST3). This clearly shows that proteomics and 
genomics analyses capture to some extent complementary aspects of melanoma biology. Using mRNA profil-
ing data of the same patient cohort (the same tumor samples, but different sections) as previously published23, 
one can correlate mRNA and protein expression signals. For these, a median correlation of 0.306 is obtained 
(Suppl. Fig. S8). This is generally in agreement with the previous studies, however, since mRNA and protein 
data were obtained from different tissue sections of the same samples, the actual correlation is probably slightly 
underestimated.
The differential expression analysis of genes and proteins provides tumor- and survival-related functions in 
short and long survival sample clusters. Although, the differentially expressed sets of genes and proteins were 
by large different, the biological functions related to the patient clusters were to a certain extent similar (see 
Suppl. Table ST4). For the short survival cluster, the significantly downregulated genes and proteins alike were 
enriched in functions such as antigen processing and presentation, TCR and interferon signalling. The three 
survival-related patient clusters did not differ in terms of mutation burden in an analysis of genes known to often 
harbor mutations in melanoma (See Suppl. Fig. S5).
Functional analysis of the 27 proteins obtained from the PLS-Cox model. Ingenuity Pathway 
Analysis (IPA) split most of the 27 proteins that were guiding the three survival clusters into two functional 
relationship networks. The first network was mostly extracellular and included proteins negatively correlated to 
survival (low expression in tumors from patients with good prognosis, i.e. long survival). The second network was 
a nuclear/cytoplasmic one, and included proteins positively correlated to survival (high in tumors from patients 
with long survival, Fig. 4A,B). A complementary IPA analysis was executed using an extended set of 160 top 
Figure 3. Proteins and mRNA exhibit differential expression among the survival-related patient clusters. Two-
way hierarchical clustering of the transcripts (A) and proteins (B) differentially expressed between the survival-
related patient clusters as per SAM analysis. Only highly significant transcripts and proteins shown (q value 
below 0.0005). Red: high expression. Blue: low expression. Patient clusters coloured as in Fig. 2B. Additional 
annotations (coloured bars at top) indicate selected patient/sample parameters: Lund genomics cluster23, TCGA 
genomics cluster, BRAF status, Melanoma type, disease stage. Additional annotations (coloured bars on the left, 
orange or green) indicate that a given transcript or protein is significantly up- or down regulated for a given 
cluster.
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proteins most strongly related to survival albeit not all strictly significant. Of these, 80 were negatively correlated 
to survival and 80 - positively correlated. Here, the proteins positively related to survival as per Cox analysis were 
enriched in functions such as RNA post-transcriptional modifications, protein synthesis and cell death. The pro-
teins negatively correlated to survival were enriched in cell-to-cell signalling and cell movement proteins.
Proteins negatively correlated to survival (high expression in short survival). Interestingly, many of the 18 pro-
teins showing negative significant correlation to survival are high-abundance plasma proteins. This may reflect 
the vascularisation aspect of melanoma metastases as well as immune component of tumor development. One 
might speculate that the lymph nodes are thought to be filters of the circulating lymph which contains enriched 
fractions of the proteins and lipids of the blood which may show in the results. Alternatively, the tumor cells 
might be “hiding” while metastasizing and covering themselves with platelets, thus exhibiting expression of plate-
let proteins (all but one of the 18 proteins are present in platelets26). Also, the negative correlation to survival 
of coagulation-related proteins (F2, PLG, FGB, FGG, FGA, KNG1) likely reflects the well-known relationship 
between cancer and thrombosis27.
The role of the copper and iron transport protein ceruloplasmin (CP) in cancer has been reported28 and it 
was found elevated in plasma of melanoma patients29, hence a negative correlation to survival could be expected. 
Human serum transferrin is a glycoprotein which is involved in iron transport. Since neoplastic cells have a high 
requirement of iron related to their rate of proliferation30, it seems logical that we found high level of transferrin 
in the poor survival cluster.
More than 5-fold higher level of the protease inhibitor ITIH4 was reported previously in sera from patients 
with hepatocellular carcinoma with good prognosis compared to patients with poor prognosis31. The ITIH4 gene 
expression was lost in multiple human solid tumors32. However, in a rat model for colon cancer, ITIH4 was one of 
four proteins that was upregulated in sera compared to wild-type rats33. The serine protease inhibitor, SERPINA1, 
has been reported to modulate invasive and metastatic capacity in lung cancer, gastric cancer, and CRC34–36. 
Elevated expression of SERPINA1 was previously correlated with advanced stage, lymph node metastasis, and 
poor prognosis37, which is in accordance to our current findings.
Complement factor H (CFH) is the main actor inhibiting complement responses by regulating the 
Complement Alternative Pathway38. CFH binds to “self marker” structures on matrix and the cell surface, e.g. 
GAG chains and sialylated sugars, and prevents further activation/attack by the complement system39. CFH may 
have dual roles in cancer, either promoting tumor progression (by immune evasion) or supporting tumor sup-
pression (by inducing an anti-inflammatory microenvironment38). Tumor cells may “hijack” the complement sys-
tem by expressing, releasing or recruiting CFH and other complement inhibitors in high amounts, thus evading 
complement attack. This has been described in ovarian, lung, glioma and colon cancer cells40–43. In addition, CFH 
has been suggested as a marker in lung adenocarcinoma44, where shorter survival time of patients with adenocar-
cinoma was associated with increased CFH staining. Data from the TCGA cohort suggest that increased mRNA 
levels of CFH are significantly related to poor prognosis in kidney carcinoma45 and urine levels of a closely related 
protein CFHR1 were negatively related to bladder cancer survival46. To our knowledge, negative relation of CFH 
protein to survival in metastatic melanoma tissue has not been reported.
Figure 4. Pathway analysis for 27 survival-related proteins. Ingenuity Pathway Analysis (IPA) for the proteins 
identified by the PLS-Cox analysis as significantly related to survival (Cox score FDR < 0.1). Protein-protein 
relationship subnetworks shown that are enriched in the 27 query proteins. (A) First subnetwork, (B) Second 
subnetwork. Blue – proteins with expression negatively correlated to survival. Red – positively correlated to 
survival. Data were analyzed through the use of IPA (QIAGEN Inc., https://www.qiagenbioinformatics.com/
products/ingenuitypathway-analysis)109.
8Scientific RepoRts |          (2019) 9:5154  | https://doi.org/10.1038/s41598-019-41625-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
A role of Vitamin D signaling and the activity of Vitamin D binding protein GC (VDBP) in melanoma is 
known47,48 and vitamin D deficiency is associated with worse prognosis49. VDBP is responsible for transporting 
Vitamin D analogues in plasma. While SNPs in VDBP were reported not to influence melanoma survival in 
a case-control study50, meta-analysis of VDBP polymorphisms suggested that VDBP rs12512631 TT genotype 
was linked to a poorer survival compared with those with TC and CC genotypes47. The involvement of VDBP in 
cancer has a complex mechanism: on one hand, VDBP enhances epithelial ovarian cancer progression51, on the 
other hand, higher circulating VDBP levels were observed in healthier melanoma patients52. Also, a meta-analysis 
including 28 studies of 12 different cancers, and analyzing VDBP protein levels vs. cancer risk found trends 
toward significance (lower risk related to high expression), suggesting a role of VDBP in cancer etiology53. The 
negative relation of VDBP expression to melanoma survival observed by us is not in agreement with some pre-
vious reports, whereas promising results were obtained by using VDBP in cancer immunotherapy54,55. However, 
these results cannot be compared directly with ours since serum levels of VDBP need not be correlated to levels 
in tumor tissue.
APG1 and 2 (Orosomucoid 1 and 2) are heavily glycosylated acute phase reactants, mainly expressed in the 
liver but also extrahepatically56,57 and increased in the circulation during acute inflammation as well as in several 
cancers including melanoma58–60. APG1 seems to be the primary acute phase responder while the proportion of 
APG1 to APG2 changes significantly in cancer59. The APGs display a multitude of biological activities such as 
acute-phase reactants, modulating immunity, and maintaining the barrier function of capillaries56,57. In addition, 
APGs are involved in binding synthetic drugs which has been described in cancer patients61–63. Aberrant gluco-
sylation of the APGs is related to pathophysiological situations including cancer64. Overall, the negative relation 
to melanoma survival of APGs detected in metastatic melanoma tissue in the current study would be in agree-
ment with previous literature describing circulating levels in cancer patients.
A recent study65 related serum albumin levels to melanoma stage in a large patient cohort showing a signifi-
cant reduction in circulating levels in stage 4 and in older patients. Albumin is a negative acute phase protein, e.g. 
levels are reduced during inflammation. The reduced levels in cancer and several other illnesses may be due to 
decreased synthesis, increased catabolism and other mechanisms66,67. In the current study, serum albumin level 
in melanoma tissue is negatively related to survival (high in patients with poor survival) which appears not in 
accordance with most other studies. However, most studies look at circulating levels and not metastatic tumor 
tissue.
Apolipoprotein B-100 (APOB) is a receptor for cholesterol which has been shown to increase melanogenesis68 
and targeting cholesterol transport in melanoma CTCs was shown to retard metastasis development69. This may 
be in line with current results of increased APOB expression in poor survival.
Alpha-1B-glycoprotein is a secreted glycoprotein with some similarity to the immunoglobulin family and 
basically very few known functions70. Interestingly, it has been described in proteomic studies of several cancer 
types like breast cancer71, oral squamous carcinoma72, in the serum of non-small cell lung cancer73, and in pancre-
atic ductal adenocarcinoma74. Here we describe for the first time a negative correlation of alpha-1B-glycoprotein 
tissue expression to melanoma survival.
Proteins positively correlated to survival (high expression in longer survival). The splicing factor SRSF3 has been 
reported as an oncogenic factor in several types of cancer75–79. However, in colorectal cancer, loss of SRSF3 was 
significantly associated with poor survival and shorter disease-free survival in early cancer stages80. It was also 
shown that loss of SRSF3 was necessary for metastatic cells to colonize the liver microenvironment in mice80. Loss 
of SRSF3 has also been shown to predispose to hepatocellular carcinoma81 and myeloid leukemia82. In this study, 
higher expression of SRSF3 was also found in the better prognosis cluster.
The transcription factor YBX1 is positively associated with a proliferative cellular state and might therefore 
be reported to be overexpressed in a variety of human cancers83–86. However, the YBX1 expression seems to be 
tightly regulated by a feedback mechanism ensuring optimal proliferation and survival of melanoma cells. The 
levels of YBX1 are also critical in melanoma cells for proliferation. High levels inhibit cell cycle progression and 
low levels induce apoptosis87. The YBX1 has been reported to correlate with bad prognosis in liver cancer88,89 
while here YBX1 is upregulated in melanoma patients with good prognosis.
Among the proteins positively correlated to survival, there are two proteasome related proteins PSMA5 and 
PSME1. The role of immunoproteasome in cancer is known90, however high expression in better prognosis 
patients is not an obvious result. In a recent meta-analysis, PSMAs were generally found to be upregulated in 
cancers, including melanoma. Expression of some members of the PSMA family correlated with poor prognosis91, 
however no melanoma prognosis data was available for the PSMA5 gene/protein that we find correlated with bet-
ter prognosis. The Proteasome activator PSME1 (PA28alpha) that has been reported to regulate presentation of T 
lymphocyte epitopes on melanoma cells92 is found here to be upregulated in good prognosis melanoma patients, 
similarly to a previous proteomics study15. Interestingly, quite to the opposite, in oral squamous cell carcinoma 
PSME1 expression has been reported to be related to poor prognosis93.
The Poly A binding proteins PABPC1 and PABPC3 function in post-transcriptional control of mRNA and 
regulate cell proliferation94. PABPC1 expression was previously reported positively correlated to survival in eso-
phageal cancer95, but this protein has also been found to be oncogenic in gastric carcinoma96.
The splicing factor HNRNPA2B1 has been reported as a candidate biomarker in lung cancer and regulator of 
epithelial-mesenchymal transition in pancreatic cancer (PDAC)97–99. Another splicing factor, HNRNPH2, was 
shown to drive anticancer drug resistance100 and to drive hepatocellular carcinoma development101. Hence, higher 
expression in good prognosis of these two factors is an unexpected result.
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Conclusion
We present a comprehensive proteomic, histopathological and genomic evaluation of malignant melanoma 
lymph node metastases. Our study is unique in applying in-depth histopathological characterisation to indi-
vidual tumor samples. This, combined with detailed clinical information, allows elucidation of an efficient set 
of proteomic prognostic biomarkers. Since many of these candidate biomarkers are known to be relatively com-
mon plasma proteins, they present a possible opportunity for development of prognostic blood-based biomarker 
panel. This work builds on our own exploratory studies19,102 as well as work by other groups15,103 but differs from 
the previous work also by a much larger study cohort. By analysing the protein data alongside the genomic data 
obtained of the same tumor tissue, we highlight the complementarity of proteomic and transcriptomic molecular 
images of melanoma.
The fact that some of the prognostic proteins have not been reported in melanoma context before, and the fact 
that some exhibit unexpected relationship to survival, only exemplifies the complexity of melanoma progression 
mechanisms.
Materials and Methods
Reagents and solutions. All chemical reagents were purchased from Sigma Aldrich (St. Louis, MO) unless 
otherwise specified. Water and organic solvents were of LC–MS quality and supplied by Merck (Darmstadt, 
Germany). All solutions were degassed by sonication before use.
tissue samples and sample preparation. 111 lymph node metastasis samples from patients with 
malignant melanoma (Stage 3 and 4), archived in the local malignant melanoma biobank were obtained from 
Skåne University Hospital, Sweden. Each sample was marked as ‘MM’ followed by identification number. Ethical 
approval was granted by Central Ethical Review board at Lund University; approval number: DNR 191/2007, 
101/2013. All patients within the study provided a written informed consent. All experiments were performed in 
accordance with relevant guidelines and regulations. The malignant melanoma biobank “Tissue bank for research 
on tumour diseases” (BD20)” is located at Barngatan 2B, 221 85 Lund, Sweden. The samples were originally snap 
frozen immediately after surgery. Frozen tissue samples from BD20 were sectioned on a cryostat into 10 µm thick 
slices (approximately 6 × 6 mm), placed into a 96 well plate and stored at −80 °C until further use. From each 
tissue, 15 to 20 slices were withdrawn for sample preparation. Patient characteristics are summarised in Table 1. 
Clinical and histopathological parameters were retrieved from patients’ clinical records, pathology reports and 
the Swedish National Population Registry. Survival was defined as time (days) from lymph node excision to 
patient’s death or censoring date.
Histopathological evaluation. Frozen sections of all lymph node metastases stained with HE were evalu-
ated by a certified pathologist. Serial sections were taken of each tumor, and at least seven slices per sample were 
examined. The tissue was assessed for its content regarding tumor, normal lymph node, necrosis, and background 
of any further component (e.g. fat or connective tissue). As previously described16,19, the tumor was then eval-
uated for its histological characteristics containing epithelioid or spindle or mixed architecture, the tumor cell 
average size (scale 1–3) and pigmentation (scale 1–3). The tumor infiltrating lymphocytes were also assessed for 
their distribution (scale 1–3) and intensity (scale 1–3) in the tumor - only those which directly infiltrated the 
metastases were taken into account. The sum of distribution and density was then summarized in a 0–6 score 
considered as immunoscore.
cDNA synthesis and BRAF DNA sequencing. Two cell lines, SK-MEL-2 and SK-MEL-28 (ATCC®, 
Manassas, USA), were used as reference BRAF wild type and V600E respectively. Total RNA was extracted from 
the cell lines or frozen tissues from the malignant melanoma patients using RNeasy mini kit (Qiagen, Venlo, 
The Netherlands). The extracted RNA were reverse transcribed to cDNA by using Superscript III First Strand 
Synthesis System kit (ThermoFisher, Waltham, MA) according to the manufacturer’s instructions. The cDNA 
was amplified with a set of primers that produced a PCR product including BRAF mutation at the position V600; 
5′-(AGCCTTACAGAAATCTCCAGGACC)-3′ and 5′-(TTGGGGAAAGAGTGGTCTCTCATC)-3′. The PCR 
conditions were 95 °C for 5 min, followed by 36 cycles of 95 °C for 30 sec, 62 °C for 30 sec, and 72 °C for 2.5 min 
with a final incubation of 72 °C for 7 min. A portion of the PCR product was amplified a second time using 
the same condition as the first PCR, and the amplification was 24 cycles, instead of 36 cycles. The PCR prod-
ucts were run on a 1% agarose gel, and DNA was extracted from the gel using a QIAquick Gel Extraction kit 
(Qiagen) according to the manufacturer’s instruction. The purified PCR products were sequenced using a primer 
5′-(TTCCACAAAGCCACAACTGG)-3′ by Eurofins Genomics (Ebersberg, Germany).
Mutation data. Mutational information for selected 1697 cancer-associated genes were obtained by targeted 
deep sequencing of the patient tumor samples with matched blood, as described previously23,104. Visualization 
of mutational information was obtained using the oncoprinter function from R package ComplexHeatmap105.
Tissue lysis and protein extraction. Frozen tissue slices were lysed with 6 M urea in 50 mM ammonium 
bicarbonate buffer (AmBic) for 30 min on ice bath. Samples were additionally vortexed for 10 min in order to pro-
mote protein extraction. After incubation with urea the lysate was sonicated for 5 min and centrifuged at 10 000 g 
at room temperature for 10 minutes. Supernatant was transferred into a new tube and the pellet was discarded. 
Protein concentration was measured using a bicinchoninic acid protein assay according to the manufacturer’s 
instructions (Micro BCA kit, Pierce/Thermo Scientific, Rockford, IL). The samples were spiked with 0.1 mg of 
internal standard – chicken lysozyme (CL, Swiss-Prot accession no. P00698).
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In-solution digestion with trypsin. A fixed amount (80 μg) of protein were reduced with 10 mM DTT 
for 1 h at 37 °C, then it was alkylated using 50 mM iodoacetamide for 30 min and kept in dark at room temper-
ature. Urea was removed from the samples using Amicon Ultra centrifugal filters (0.5 mL, 10 kDa, Millipore, 
Ireland) according to the manufacturer’s instructions. Briefly, the protein samples were mixed with 200 μL of 
50 mM AmBic, then centrifuged at 14 000 g at room temperature for 20 minutes and the eluates were discarded. 
These steps were repeated two more times. The samples were transferred to an Eppendorf tube and digested with 
sequencing grade trypsin (Promega, Madison, WI) in a ratio 1:100 w/w (trypsin:protein) overnight at 37 °C. 
The digestion was stopped by adding formic acid till 1% as final concentration. The samples were dried using a 
centrifugal evaporator and resuspended in 80 μL of 0.1% formic acid and centrifuged for 5 min at 10 000 g. The 
supernatants were stored at −80 °C until further use. Prior to injection onto LC–MS/MS, 20 µL of samples were 
mixed with 20 µL of peptide retention time calibration mixture (PRTC, Pierce/Thermo Scientific, Rockford, IL, 
20 fmoL/mL).
LC-Ms/Ms Analysis of the tumor lysate digests. Online chromatography was performed with a 
Thermo Easy nLC 1000 system (Thermo Fisher Scientific) coupled online to a Q-Exactive Plus mass spectrome-
ter (Thermo Scientific, San José, CA). The peptides were first loaded onto a trap column (Acclaim1 PepMap 100 
pre-column, 75 µm, 2 cm, C18, 3 mm, 100 Å, Thermo Scientific, San José, CA) and then separated on an analytical 
column (EASY-Spray column, 25 cm, 75 µm ID, PepMap RSLC C18, 2 mm, 100 Å, Thermo Scientific, San José, 
CA). Flow rate of 300 nL/min and a column temperature of 35 °C were utilised. A gradient was applied, using 
solvent A (0.1% formic acid) and solvent B (0.1% formic acid in acetonitrile). The gradient went from 5% to 40% 
B in the first 120 min, followed by raise to 90% B in the next 5 min, which was maintained for 10 min. To avoid 
carryover, each sample analysis was followed by a blank injection (water containing 0.1% formic acid). Mass 
spectrometry data were measured using a data-dependent top-15 method. Full MS scans were acquired over m/z 
350–1800 range with resolution of 70 000 (at m/z 200), target AGC value of 1∙106 and maximum injection time 
of 100 ms. Selected ions were fragmented in the HCD collision cell with normalised collision energy of 30%, and 
tandem mass spectra were acquired in the Orbitrap mass analyzer with resolution of 17 500 (at m/z 200), target 
AGC value of 1∙106 and maximum injection time of 120 ms. The ion selection threshold was set to 4.2∙104 and 
dynamic exclusion was 20 s.
proteomics data analysis. The LC-MS/MS raw files were analyzed with Proteome Discoverer 2.1 (Thermo 
Scientific, San José, CA) for protein identification and quantitation. The files were searched against the UniProtKB 
human database (released May 2016) excluding isoforms. The search was performed with the following param-
eters: carbamidomethylation as static modification, oxidation of methionine as dynamic modification, 20 ppm 
precursor tolerance and 0.02 Da fragment tolerance. Up to two missed cleavages for tryptic peptides was allowed. 
Filters: high confidence at peptides and protein levels were applied (FDR 0.01). Protein intensities were log2 trans-
formed, followed by sample median subtraction using R (version 2.41–3).
Multivariate survival analysis. We have used unsupervised and supervised approaches to linking 
proteomic data to survival. The unsupervised method was performed using consensus clustering in R with 
ConsensusClusterPlus library (version 1.42.0). The supervised approach is based on PLS-Cox regression sim-
ilar to that of Nguyen and Rocke24. The PLS-step of the model is used to reduce the high dimensionality of the 
proteomic data, while Cox regression was used on the first PLS component. We use a similar approach as Bair et 
al.22 to assess the performance of this model. For cross-validation, the dataset is split into two subsets; the first is 
used to fit the model, the second to evaluate its performance. This process is repeated 100 times and the results 
of all iterations are averaged. Simultaneously, we extract the most important features, i.e. proteins, using rank 
products24,106 of the PLS loadings. Correction for multiple testing with Benjamini-Hochberg approach results in 
9 proteins which are significantly positively correlated to long survival and 18 which are significantly negatively 
correlated at adjusted significance level of 0.05. We performed this analysis both for the full sample set (N = 111) 
as well as for a subset (N = 94) wherein all samples contain at least 15% tumor. The supervised survival analysis 
was performed using peptide data as well, but the identified sample clusters showed less significant relationships 
to survival.
For the Kaplan-Meier survival analysis, the survdiff function in R (version 2.41–3) was used, which imple-
ments the log-rank test.
Differentially expressed genes and proteins for the survival-related patient clusters were elucidated using the 
SAM method25, applying multiple testing correction as described107. Gene expression data for the patient samples 
analysed in the current study were obtained in a previous study using the same sample set but different tissue 
sections23.
By using the pheatmap library in R, two clustered heatmaps were built for the differentially expressed proteins 
and genes obtained from SAM analysis (FDR < 0.0005). Melanoma type, disease stage, BRAF status, TCGA clas-
sification and four-category classification of Jönsson et al.23 were used as annotation terms. Comparison of clinical 
and histopathological parameters between the sample clusters was performed by chi-squared test (categorical var-
iables) and by Kruskal-Wallis test (quantitative nonparametric variables). Differences were considered significant 
when p-value < 0.05 (without multiple testing adjustment).
The transcriptomic dataset of melanoma lymph node metastases from the TCGA database16 was used for val-
idation of the candidate proteomic survival biomarkers found in our study. The SurvExpress tool108 was applied 
to assess if query transcripts were promising predictors of survival.
protein set functional analysis. Functional analysis of the protein sets identified with PLS-Cox regression 
and correlation analysis with tumor content was conducted using IPA, Ingenuity Pathway Analysis (Qiagen, 
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Redwood City, CA, USA)109, in particular by generating networks of protein-protein functional relationships. As 
background, the set of proteins detected in >70% of the samples was used.
Functional analysis of lists of proteins mentioned above was also performed using the Panther server110. 
Overrepresentation of specific functional annotations within the protein lists was determined by Fisher’s exact 
test, the background protein set consisted of all proteins detected. Gene Ontology annotations, SwissProt key-
words, and Reactome and KEGG pathways were used as annotation terms for the enrichment analysis.
Data Availability
The proteomics dataset associated with the current article is publicly available in ProteomeXchange (http://www.
proteomexchange.org/), dataset identifier: PXD009630.
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